Home Page
           

About NanoCor
. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . .

NanoCor Therapeutics, Inc. is a biotechnology company focused on developing novel molecular therapies for patients with cardiovascular disease.
Learn more about NanoCor.

About Chronic Heart Failure
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

What is Congestive Heart Failure?
Living with Heart Failure
American Heart Association

 
Research & Development Research and Development
Carfostin™
 
Technology Technology
Biological Nanoparticle (BNPs™) Technology
Self-complimentary vector technologies
 
Building Blocks   For Investors
Investor Resources, Market Opportunity, etc
 
CHF Spotlight on CHF
Chronic heart failure overview, statistics and progress

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.

        Copyright © 2009 NanoCor Therapeutics. All Rights Reserved.                    |                  Chapel Hill, North Carolina 27514                   |                   Disclaimer